Age no barrier to vorapaxar use in ACS

The protease-activated receptor 1 inhibitor vorapaxar offers the same benefits to older and younger patients with non-ST segment elevation acute coronary syndromes, shows further analysis of the TRACER trial.

Source: MedWire News - June 14, 2016 Category: Consumer Health News Tags: Acute coronary syndromes Source Type: news